Physician profile
Martha Galvan
NPI 1205274040
$5,123.02
in general payments reported to CMS, 2019-2025
23 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,673 · 2020: $335 · 2021: $128 · 2022: $162 · 2023: $706 · 2024: $971 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,825.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $940.67 | 2019-2025 | Tezspire, Fasenra |
| Genzyme Corporation | $877.64 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $673.01 | 2019-2025 | Dupixent |
| Alk-Abello, INC | $365.08 | 2019-2025 | Odactra, Grastek, Ragwitek |
| Amgen INC. | $365.00 | 2021-2025 | Tezspire |
| Glaxosmithkline, LLC. | $345.70 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $284.92 | 2019-2025 | Hizentra |
| Genentech USA, INC. | $284.66 | 2019-2025 | Xolair |
| Grifols USA, LLC | $168.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $158.07 | 2025 | |
| Optinose US, INC. | $137.50 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.28 | 2020-2025 | Cuvitru |
| Octapharma USA, INC. | $67.68 | 2024-2025 | Panzyga, Cutaquig |
| Ionis Pharmaceuticals, INC. | $66.66 | 2025 | Dawnzera |
| Ars Pharmaceuticals Operations, INC. | $50.16 | 2025 | Neffy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $44.40 | 2019-2024 | Ruconest |
| Shire North American Group INC | $41.43 | 2019 | |
| Pfizer INC. | $40.47 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.39 | 2019 | |
| Horizon Therapeutics Plc | $20.75 | 2020 | |
| Incyte Corporation | $20.70 | 2025 | Opzelura |
| Hikma Pharmaceuticals USA | $17.68 | 2023 | Ryaltris |
| Circassia INC. | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Galvan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.